Evidence map›Paper›PMID 30677458›Full record

ArticleJournal of hepatology2019

Hepatic PPARα is critical in the metabolic adaptation to sepsis.

Réjane Paumelle, Joel T Haas, Nathalie Hennuyer, Eric Baugé, Yann Deleye, Dieter Mesotten, Lies Langouche, Jonathan Vanhoutte, Céline Cudejko, Kristiaan Wouters and 20 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Diabetes Management Strategies in Intensive Care Settings.The Medical clinics of North America · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Mechanisms of sepsis-induced acute liver injury: a comprehensive review.Frontiers in cellular and infection microbiology · 2025
    Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 5 institutions in 5 countries.

Réjane PaumelleUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Joel T HaasUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Nathalie HennuyerUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Eric BaugéUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Yann DeleyeUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Dieter MesottenLaboratory of Critical Care Medicine, Dept Cellular and Molecular Medicine, KU Leuven, University Hospitals Leuven, Herestraat 49 Bus 503, B-3000 Leuven, Belgium.
Lies LangoucheLaboratory of Critical Care Medicine, Dept Cellular and Molecular Medicine, KU Leuven, University Hospitals Leuven, Herestraat 49 Bus 503, B-3000 Leuven, Belgium.
Jonathan VanhoutteUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Céline CudejkoUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Kristiaan WoutersMaastricht University, Dept. of Internal Medicine, Maastricht, The Netherlands.
Sarah Anissa HannouUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Vanessa LegryUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Steve LancelUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Fanny LalloyerUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Arnaud PolizziInstitut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France.
Sarra SmatiInstitut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France.
Pierre GourdyInstitut National de La Santé et de La Recherche Médicale (INSERM), UMR1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.
Emmanuelle VallezUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Emmanuel BouchaertUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Bruno DerudasUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Hélène DehondtUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Céline GheeraertUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Sébastien FleuryUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Anne TailleuxUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Alexandra MontagnerInstitut National de La Santé et de La Recherche Médicale (INSERM), UMR1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; Institut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France.
Walter WahliInstitut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France; Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Clinical Sciences Building, 11 Mandalay Road, Singapore 308232, Singapore; Center for Integrative Genomics, Université de Lausanne, Le Génopode, CH-1015 Lausanne, Switzerland.
Greet Van Den BergheLaboratory of Critical Care Medicine, Dept Cellular and Molecular Medicine, KU Leuven, University Hospitals Leuven, Herestraat 49 Bus 503, B-3000 Leuven, Belgium.
Hervé GuillouInstitut National de La Recherche Agronomique (INRA), UMR1331 ToxAlim, Toulouse, France.
David DombrowiczUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
Bart StaelsUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France. Electronic address: bart.staels@pasteur-lille.fr.
Inserm · FRKU Leuven · BEToxicologie Alimentaire · FRMaastricht University · NLNanyang Technological University · SG

Funding

European Research Council 785809
6 · The paper itself

Abstract

BACKGROUND &

aimsAlthough the role of inflammation to combat infection is known, the contribution of metabolic changes in response to sepsis is poorly understood. Sepsis induces the release of lipid mediators, many of which activate nuclear receptors such as the peroxisome proliferator-activated receptor (PPAR)α, which controls both lipid metabolism and inflammation. We aimed to elucidate the previously unknown role of hepatic PPARα in the response to sepsis.

methodsSepsis was induced by intraperitoneal injection of Escherichia coli in different models of cell-specific Ppara-deficiency and their controls. The systemic and hepatic metabolic response was analyzed using biochemical, transcriptomic and functional assays. PPARα expression was analyzed in livers from elective surgery and critically ill patients and correlated with hepatic gene expression and blood parameters.

resultsBoth whole body and non-hematopoietic Ppara-deficiency in mice decreased survival upon bacterial infection. Livers of septic Ppara-deficient mice displayed an impaired metabolic shift from glucose to lipid utilization resulting in more severe hypoglycemia, impaired induction of hyperketonemia and increased steatosis due to lower expression of genes involved in fatty acid catabolism and ketogenesis. Hepatocyte-specific deletion of PPARα impaired the metabolic response to sepsis and was sufficient to decrease survival upon bacterial infection. Hepatic PPARA expression was lower in critically ill patients and correlated positively with expression of lipid metabolism genes, but not with systemic inflammatory markers.

conclusionDuring sepsis, Ppara-deficiency in hepatocytes is deleterious as it impairs the adaptive metabolic shift from glucose to FA utilization. Metabolic control by PPARα in hepatocytes plays a key role in the host defense against infection. LAY SUMMARY: As the main cause of death in critically ill patients, sepsis remains a major health issue lacking efficacious therapies. While current clinical literature suggests an important role for inflammation, metabolic aspects of sepsis have mostly been overlooked. Here, we show that mice with an impaired metabolic response, due to deficiency of the nuclear receptor PPARα in the liver, exhibit enhanced mortality upon bacterial infection despite a similar inflammatory response, suggesting that metabolic interventions may be a viable strategy for improving sepsis outcomes.

Indexed as

Adaptation, PhysiologicalAnimalsBacterial InfectionsFatty AcidsGlucoseHumansInflammationLiverMiceMice, Inbred C57BLPPAR alphaSepsisFatty AcidsGlucosePPAR alphaHepatocytesInflammationMetabolismNuclear receptorsSepsis

Identifiers

PMID30677458
PMCPMC6774768
OpenAlexW2912783332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.